The FDA issued draft guidance intended to shape how sponsors can submit and manage personalized genome editing therapies for rare genetic diseases. The proposal introduces a regulatory framework for Individualized Feature Space (IFS), designed to define acceptable variation for genome-edited components within a single Biologics License Application (BLA). As described, IFS can allow some differences across patients—such as permitted ranges of gRNA spacer sequences—without requiring additional clinical trials, provided the editing outcomes remain within the pre-defined scope. The guidance is positioned to reduce development friction for individualized treatments while maintaining scientific and regulatory controls. A separate report on gene-editing shares pointed to a supportive regulatory signal from the agency’s constructiveness, alongside data catalysts from the ESGCT annual congress. Investors linked the FDA draft guidance to potential de-risking opportunities. The FDA is soliciting public comment through November 27, with the draft guidance offering a concrete path for how sponsors might operationalize individualization within a single regulatory approval framework.